Drugs that contain Amifampridine Phosphate

1. List of Firdapse drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11274332 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(9 years from now)

US11274331 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(9 years from now)

US11268128 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(9 years from now)

US11060128 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(9 years from now)

US10793893 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
May, 2034

(11 years from now)

US10626088 CATALYST PHARMS Determining degradation of 3,4-diaminopyridine
Feb, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 28, 2023
Orphan Drug Exclusivity (ODE) Nov 28, 2025
New Patient Population (NPP) Sep 29, 2025

NCE-1 date: November, 2022

Market Authorisation Date: 28 November, 2018

Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic